Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:BVXVNASDAQ:NEPTNASDAQ:THMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.64-2.5%$4.42$3.39▼$16.00$51.54M0.759,349 shs33,833 shsBVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shsTHMOThermoGenesis$0.00$0.00▼$0.60$1K1.175,900 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-2.52%-4.13%+22.43%-39.43%-60.68%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%THMOThermoGenesis0.00%0.00%0.00%-66.67%-99.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.5713 of 5 stars3.55.00.00.02.81.71.3BVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ATHMOThermoGenesisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00546.55% UpsideBVXVBiondVax Pharmaceuticals 0.00N/AN/AN/ANEPTNeptune Wellness Solutions 0.00N/AN/AN/ATHMOThermoGenesis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest THMO, AVTX, BVXV, and NEPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K114.21N/AN/A$12.80 per share0.36BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ANEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00THMOThermoGenesis$9.61M0.00N/AN/A($0.99) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)BVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ATHMOThermoGenesis-$17.98M-$5.14N/AN/AN/AN/AN/AN/AN/ALatest THMO, AVTX, BVXV, and NEPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ATHMOThermoGenesisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61BVXVBiondVax PharmaceuticalsN/A4.124.12NEPTNeptune Wellness SolutionsN/A0.230.10THMOThermoGenesisN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%BVXVBiondVax Pharmaceuticals11.83%NEPTNeptune Wellness Solutions14.44%THMOThermoGenesis5.78%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%BVXVBiondVax Pharmaceuticals6.03%NEPTNeptune Wellness Solutions5.10%THMOThermoGenesis78.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.50 millionNot OptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableTHMOThermoGenesis407.95 million1.75 millionNot OptionableTHMO, AVTX, BVXV, and NEPT HeadlinesRecent News About These CompaniesThe Ice Water Hack: How Aqua Sculpt Boosts Thermogenesis for Fat LossMarch 10, 2025 | globenewswire.comIce Water Hack: How Aqua Sculpt Improves Thermogenesis for Weight LossFebruary 20, 2025 | globenewswire.comNorth American Morning Briefing: Stock Futures, -2-September 19, 2024 | morningstar.comIs Thermogenesis Holdings Inc Stock (THMO) a Good Investment?August 8, 2024 | aaii.comThermoGenesis Holdings (OTC:THMO) Stock Quotes, Forecast and News SummaryJuly 28, 2024 | benzinga.comThermoGenesis Holdings (OTC:THMO) Stock, Short Interest ReportJuly 28, 2024 | benzinga.comWhy Is ThermoGenesis (THMO) Stock Down 37% Today?June 12, 2024 | investorplace.comTHMO Stock Earnings: ThermoGenesis Holdings Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | investorplace.comThermoGenesis Holdings, Inc. (NASDAQ:THMO) Is About To Turn The CornerFebruary 27, 2024 | finance.yahoo.comThermoGenesis Holdings, Inc.January 10, 2024 | thestreet.comThermoGenesis Holdings Stock (NASDAQ:THMO) Dividends: History, Yield and DatesDecember 16, 2023 | benzinga.comShareholders Will Probably Hold Off On Increasing ThermoGenesis Holdings, Inc.'s (NASDAQ:THMO) CEO Compensation For The Time BeingDecember 8, 2023 | finance.yahoo.comThermoGenesis Holdings Recent Insider ActivityNovember 21, 2023 | benzinga.comThermoGenesis Holdings, Inc.: ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 15, 2023 | finanznachrichten.deThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comThermoGenesis Q3 Earnings PreviewNovember 12, 2023 | msn.comHere's what Wall Street expects from ThermoGenesis's earnings reportNovember 12, 2023 | markets.businessinsider.comThermoGenesis Holdings Inc THMONovember 12, 2023 | morningstar.comThermoGenesis Holdings Earnings PreviewNovember 10, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTHMO, AVTX, BVXV, and NEPT Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.64 -0.12 (-2.52%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.64 0.00 (-0.11%) As of 06/20/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.BiondVax Pharmaceuticals NASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. ThermoGenesis NASDAQ:THMOThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
